The Emergence Of A New Medicinal Platform: mRNA
Executive Summary
In the first of a three-part series on the evolution of mRNA manufacturing, this article looks back to before the pandemic, when dogged mRNA researchers and entrepreneurs labored in obscurity pursuing the dream of revolutionizing health care by commandeering the body’s own protein building process to generate quicker, cheaper vaccines and therapeutics. Then the mRNA COVID-19 vaccines stunned the world.
You may also be interested in...
Syngene COO On Delivering Cost Gains For mRNA Products
Syngene’s COO, Mahesh Bhalgat, tells Scrip the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.
Eager But Wary: Industry Seeks More Useful, More Detailed Remote Regulatory Assessment Processes
Responses to FDA draft guidance suggest more promptness while also more elaborate processes for agency decision making based on remote methods. Questions include what’s voluntary, what’s mandatory, what can be decided remotely, and how to remotely move on from warning letters.
Eager But Wary: Industry Seeks More Useful, More Detailed Remote Regulatory Assessment Processes
Responses to US FDA draft guidance suggest more promptness while also more elaborate processes for agency decision making based on remote methods. Questions include what’s voluntary, what’s mandatory, what can be decided remotely, and how to remotely move on from warning letters.